Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)

[Manouche]

Conclusions:

High long-term response rates (80.4% at 24 months; 73.2% at 72 months) were achieved with ropeginterferon alfa-2b treatment in the low-risk PV population when the dose was optimized on an individual basis. No specific baseline characteristics among low-risk PV patients appear to be associated with long-term response to ropeginterferon alfa-2b. However, the PROUD-PV/CONTINUATION-PV studies show that - as hypothesized based on the Low-PV trial data - some low-risk patients require and can tolerate high doses, and that the optimal dose of ropeginterferon alfa-2b varies substantially between patients.

ash.confex.com/ash/2023/web...

[hunter5582]

The conclusion that "the optimal dose of ropeginterferon alfa-2b varies substantially between patients" makes good intuitive sense. It certainly reflects what we see in discussion here on the forum.

Do you have the link to the article available?

Thanks for posting.

[Manouche in reply to hunter5582]

Here it is: ash.confex.com/ash/2023/web...

[hunter5582 in reply to Manouche]

Thanks. Interesting article. The individualized dosing needed for Besremi is an important part of using it successfully. As a case in point, I recently bumped my Besremi dose up to 175mcg. My recent CBC shows a drop in NEUT to 1.05, just barely above the cutoff we set of 1.00. As effective as Besremi can be, there can be unwanted effects too. Individualized care is critical for success.

[monarch5000]

"the optimal dose of ropeginterferon alfa-2b varies substantially between patients" is 30 year old news to veteran users of the short acting interferon alfa's (e.g. Intron-A, Roferon) and the pegylated interferons (e.g. Pegasys, Pegintron).

[PhysAssist]

Hi Manouche,

Thanks for the article and link[s].

I did a quick browse through the list and found these other articles that some here might find helpful:

4560 Germline MPL Mutations May be a Rare Cause of “Triple-Negative” Thrombocytosis

ash.confex.com/ash/2023/web...

Type 1/like Calr Mutation in Momelotinib-Treated Patients with Myelofibrosis Is the Most Prominent Predictor of Drug Survival and Longevity without Transplant

ash.confex.com/ash/2023/web...

MRI Reliably Captures Bone Marrow Metrics in Myelofibrosis

ash.confex.com/ash/2023/web...

Ruxolitinib Treatment in Polycythemia Vera Results in Reduction in JAK2 Allele Burden in Addition to Improvement in Hematocrit Control and Symptom Burden

ash.confex.com/ash/2023/web...

Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes

ash.confex.com/ash/2023/web...